Symbol="XBIO"
AssetType="Common Stock"
Name="Xenetic Biosciences Inc"
Description="Xenetic Biosciences, Inc., a biopharmaceutical company, is focused on advancing XCART, a customized chimeric antigen receptor T (CAR T) platform technology designed to target patient-specific tumor neoantigens. The company is headquartered in Framingham, Massachusetts."
CIK="1534525"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="40 SPEEN STREET, SUITE 102, FRAMINGHAM, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="5520600"
EBITDA="-5746008"
PERatio="None"
PEGRatio="0"
BookValue="8.48"
DividendPerShare="0"
DividendYield="0"
EPS="-3.84"
RevenuePerShareTTM="1.313"
ProfitMargin="0"
OperatingMarginTTM="-3.126"
ReturnOnAssetsTTM="-0.237"
ReturnOnEquityTTM="-0.391"
RevenueTTM="1923800"
GrossProfitTTM="1160700"
DilutedEPSTTM="-3.84"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.557"
AnalystTargetPrice="40"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="3.615"
PriceToBookRatio="0.433"
EVToRevenue="0.117"
EVToEBITDA="1.08"
Beta="2.873"
num_52WeekHigh="10"
num_52WeekLow="2.401"
num_50DayMovingAverage="3.381"
num_200DayMovingAverage="4.316"
SharesOutstanding="1516700"
DividendDate="2019-06-25"
ExDividendDate="None"
symbol="XBIO"
open="4.16"
high="4.16"
low="3.59"
price="3.64"
volume="21222.00"
latest_trading_day="2023-07-14"
previous_close="4.00"
change="-0.36"
change_percent="-9.0000%"
aroon_positive_momentum_days="33"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="33"
Volume_recent_avg="44434"
Change_recent_avg="0.01"
Delta_recent_avg="0.2"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.63"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="33"
Aroon_momentum_negative="67"
image_negative_thumbnail_id_1="148"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0028.jpeg"
image_negative_thumbnail_id_2="1131"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0164.jpeg"
image_neutral_thumbnail_id_1="530"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0069.jpeg"
image_neutral_thumbnail_id_2="567"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0032.jpeg"
image_positive_thumbnail_id_1="666"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0042.jpeg"
image_positive_thumbnail_id_2="970"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0132.jpeg"
image_professor_thumbnail_id_1="1195"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0029.jpeg"
image_professor_thumbnail_id_2="1190"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0024.jpeg"
